<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487706</url>
  </required_header>
  <id_info>
    <org_study_id>DTG_HD</org_study_id>
    <nct_id>NCT02487706</nct_id>
  </id_info>
  <brief_title>Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease</brief_title>
  <official_title>Removal of Dolutegravir by Hemodialysis in HIV-infected Patients With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacio Lluita Contra la SIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on the capacity of hemodialysis to remove dolutegravir (DTG) from plasma in patients
      with end-stage renal disease (ESRD) on hemodialysis (HD) are lacking. If DTG was removed from
      plasma by HD, it would be possible to have subtherapeutic drug concentrations at the end of
      HD sessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of chronic renal disease and end-stage renal disease (ESRD) is increasing in
      the HIV-positive population. This means that an increasing number of HIV-infected patients
      will need renal replacement therapy.However, little is known about DTG removal from plasma by
      HD in patients with ESRD.

      Objective: to evaluate the effect of HD on DTG clearance as well as on DTG plasma
      concentrations at steady state in HIV-infected patients with ESRD undergoing HD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemodialysis extraction ratio of dolutegravir</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hemodialysis clearance of dolutegravir</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients presenting adverse events related to dolutegravir</measure>
    <time_frame>From Baseline to day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Dolutegravir 50mg/day per 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg/day per 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Dolutegravir 50mg/day per 5 days</description>
    <arm_group_label>Dolutegravir 50mg/day per 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age 1 years old or older.

          2. HIV documented infection (western blot)

          3. ESRD undergoing routine hemodialysis

          4. Stable antiretroviral treatment (no changes within the prior 2 weeks)

          5. Signature of informed consent

        Exclusion Criteria:

          1. Inadequate adherence to antiretroviral treatment (&lt;90% in the week prior to
             inclusion).

          2. Clinical evidence or suspicion that the patient will not be able to comply with the
             study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>HIV-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

